RYTM: HO launch gains traction, Prader-Willi trials advance, and financials support robust investment
The business is advancing three rare disease pillars, with a strong HO launch showing broad prescriber engagement and favorable payer trends. Prader-Willi development is progressing with positive phase II data and strategic plans for pivotal trials. Financially, the company is well-resourced to inv…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.